1-14 of 14
Sung-Bae Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Rebecca A. Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O’Shaughnessy, Steven J. Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J. Wongchenko, Sarah-Jayne Reilly, Nicholas Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4329–4338.
https://doi.org/10.1158/1078-0432.CCR-24-0465
Published: 01 October 2024
View article titled, Ipatasertib plus Paclitaxel for Patients with <em>PIK3CA</em>/<em>AKT1</em>/<em>PTEN</em>-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
Open the PDF for Ipatasertib plus Paclitaxel for Patients with <em>PIK3CA</em>/<em>AKT1</em>/<em>PTEN</em>-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Tira J. Tan, Sarah Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A. Traina, Carey Anders, Joe Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1240–1247.
https://doi.org/10.1158/1078-0432.CCR-23-2513
Published: 01 April 2024
View article titled, Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Open the PDF for Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios, Steven J. Isakoff, Sung-Bae Kim, Marie-Paule Sablin, Shigehira Saji, Peter Savas, Gregory A. Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Ruffo Freitas-Junior, Yeesoo Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H. Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 767–778.
https://doi.org/10.1158/1078-0432.CCR-23-2084
Published: 16 February 2024
View article titled, First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Open the PDF for First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

David W. Cescon, John Hilton, Serafin Morales Murilo, Rachel M. Layman, Timothy Pluard, Belinda Yeo, In Hae Park, Louise Provencher, Sung-Bae Kim, Young-Hyuck Im, Anastasia Wyce, Anu Shilpa Krishnatry, Kirsty Hicks, Qu Zhang, Olena Barbash, Ahmed Khaled, Thierry Horner, Arindam Dhar, Mafalda Oliveira, Joseph A. Sparano
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 334–343.
https://doi.org/10.1158/1078-0432.CCR-23-0133
Published: 17 January 2024
View article titled, A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer
Open the PDF for A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Glenn J. Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W. Bowles, Deborah J. Wong, Alan L. Ho, Sung-Bae Kim, Francis Worden, Tak Yun, Xianzhang Meng, Jan M. Van Tornout, Maureen G. Conlan, Hyunseok Kang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4555–4563.
https://doi.org/10.1158/1078-0432.CCR-23-1030
Published: 14 November 2023
View article titled, A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Open the PDF for A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract PO-008: Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122

Anthony T. C. Chan, Victor Ho Fun Lee, Ruey-Long Hong, Myung-Ju Ahn, Wan Qin Chong, Anna Spreafico, Sung-Bae Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Ramona F. Swaby, Bo Wei, Andrea Webber, John Kang, Burak Gumuscu, Jianda Yuan, Lillian Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-008.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-008
Published: 15 September 2023
View article titled, Abstract PO-008: Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122
Journal Articles

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3277–3286.
https://doi.org/10.1158/1078-0432.CCR-21-0985
Published: 02 August 2022
View article titled, Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Open the PDF for Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Özgüroğlu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 106–115.
https://doi.org/10.1158/1078-0432.CCR-20-3955
Published: 05 January 2022
View article titled, A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Open the PDF for A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6156–6163.
https://doi.org/10.1158/1078-0432.CCR-21-2103
Published: 15 November 2021
View article titled, Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Open the PDF for Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5818–5827.
https://doi.org/10.1158/1078-0432.CCR-21-1584
Published: 01 November 2021
View article titled, Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Eun Joo Kang, Myung-Ju Ahn, Chan-Young Ock, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung-Ho Nam, Sung-Bae Kim, Bhumsuk Keam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5272–5279.
https://doi.org/10.1158/1078-0432.CCR-21-1061
Published: 01 October 2021
View article titled, Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma
Open the PDF for Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma in another window
Journal Articles

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woog Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (3): 544–552.
https://doi.org/10.1158/1078-0432.CCR-14-1756
Published: 01 February 2015
View article titled, Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Open the PDF for Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck in another window
Includes: Supplementary data
Journal Articles

Fluorodeoxyglucose positron emission tomography as guidance for primary treatment in patients with squamous cell carcinomas of the oropharynx

Jong-Lyel Roh, Sang Yoon Kim, Jae Seung Kim, Seung-Ho Choi, Soon Yuhl Nam, Sung-Bae Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): A24.
Published: 15 August 2014
View article titled, Fluorodeoxyglucose positron emission tomography as guidance for primary treatment in patients with squamous cell carcinomas of the oropharynx
Journal Articles

Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy

Min Kyoung Kim, Kyung-Ja Cho, Gui Young Kwon, Seung-Il Park, Yong Hee Kim, Jong Hoon Kim, Ho-Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Sung-Bae Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (13): 4225–4231.
https://doi.org/10.1158/1078-0432.CCR-07-4848
Published: 01 July 2008
View article titled, Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
Open the PDF for Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy in another window